<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Sage Therapeutics' revenue and expenses shift in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/14/2025 07:27pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Sage Therapeutics experienced a total revenue of $12.82 million during Q4 2024, reflecting a significant financial activity period for the company. However, the specific expenses for the same period are not available, which makes it challenging to provide a comprehensive analysis of the company's financial health during that time. The absence of expense data limits a detailed assessment of Sage Therapeutics' financial performance in Q4 2024.


|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|SAGE|SAGE.O|Sage Therapeutics|2024 Q1|7902000||185|
|SAGE|SAGE.O|Sage Therapeutics|2024 Q2|8654000||185|
|SAGE|SAGE.O|Sage Therapeutics|2024 Q3|1.1871E7||185|
|SAGE|SAGE.O|Sage Therapeutics|2024 Q4|1.2816E7||185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:S,comeFrom:"AInvestShareLink",events:[],answerSource:o}],fetch:{},error:p,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:o,cache_builder:a,reply_action:"Answer",execute_mode:G,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Sage Therapeutics' revenue and expenses shift in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Sage Therapeutics' revenue and expenses shift in Q4 2024?\",\"user_id\":\"dp19317190\",\"user_name\":\"\",\"trace_id\":\"f26edb7d-1e7b-48f2-a0e3-0cc86171d811\",\"session_id\":\"f26edb7d-1e7b-48f2-a0e3-0cc86171d811\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|Total Expenses[20241231]|Report End Date|\n|---|---|---|---|---|---|---|\n|SAGE|Sage Therapeutics|$7.16|3.62%|$12.82 million||20241231|\n",query_data:{number:h,title:H,query_type:j,condition:a,model_sql:T,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d}}}],answer_chain_name:U,agent_mode:V,native_answer:a,come_from:a,text_answer:S,trace_id:i,cost:15169,event_names:a,question:g,fallback_type:W,input_type:X,fall_back_reason:{fall_back_type:W,risk_detail:{matched_words:[]}},session_id:i,first_return_cost:2582,cache_type:a,question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:Y,remote_svc:o,slots:[],answer_type:G,user_id:y,skill_name:I},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:y,question:g,source:o,raw_question:g,version:"3.4.1",action_name:I,nlu:{entity:[{type:Z,value:q,market:k}]},deep_research:c,deep_thinking:c,agent_mode:V},extra:{}},{answer_path:z,section:{id:A,info_texts:["Thinking"],show_type:B,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:z,section:{id:A,info_texts:["Querying Stock: SAGE Revenue (Q4 2024), Expenses (Q4 2024)"],show_type:B,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:H,thought:"The user wants to analyze Sage Therapeutics' revenue and expense shifts in Q4 2024. I should focus on the company's revenue and expense data for Q4 2024. I will use FinQuery for the data mentioned above."}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:z,section:{id:A,info_texts:["Generating Answer"],show_type:B,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:C,voice_txt:"S",text_answer:_,rich_text:_,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:C,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:H,query_type:j,trace_data:a,index:h,model_sql:T,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:C,voice_txt:".\n\n",text_answer:$,rich_text:$,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:t,market_id:k,name:m,domain:Z},pos:d,section_id:s,txt:m,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:aa,choice:[],result_page:{components:[{uuid:"53b4b78babe8faf6",config:{score:16,show_type:ab,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:101,title:"柱状图",render:{x:u,y:[D]},title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ac,h2:a},show_type:J}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:K,key:K,label:"hq_code",source:L,type:f},{domain:E,feKey:M,index_name:M,key:M,label:K,origin_index:"stock code",source:L,type:f,unit:a},{domain:E,feKey:N,index_name:N,key:N,label:"name",origin_index:"stock name",source:L,type:f,unit:a},{feKey:u,index_name:u,key:u,label:"date",origin_index:u,type:"DATE"},{domain:E,feKey:D,index_name:D,key:D,label:a,source:a,timestamp:a,type:ad,unit:ae},{domain:E,feKey:O,index_name:O,key:O,label:a,source:a,timestamp:a,type:ad,unit:ae},{index_name:af,key:af,type:f}],condition:"[{\"sonSize\":4,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL SAGE.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"SAGE.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":2,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Expenses\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{code:t,"Total Revenue":7902000,Ticker:q,market_code:k,Date:"2024 Q1",Name:m},{code:t,"Total Revenue":8654000,Ticker:q,market_code:k,Date:"2024 Q2",Name:m},{code:t,"Total Revenue":11871000,Ticker:q,market_code:k,Date:"2024 Q3",Name:m},{code:t,"Total Revenue":12816000,Ticker:q,market_code:k,Date:"2024 Q4",Name:m}],meta:{extra:{}},row_count:h,status_code:d,status_msg:"ok"},category:"generic",chart_type:"bar",show_type:ab,title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ac,h2:a},show_type:J},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"53b4b78babe8faf6\"}]"},render_for:P},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"dd4d236a-0998-43ce-a9aa-545db0558810"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:C,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:z,section:{id:A,info_texts:["Completed"],show_type:B,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:aa,choice:[{display_text:v,query_text:v,trace_info:{item_id:"0e807dcf95fa27073d22f0d2f37d4189",item_type:n,item_name:v,rec_info:ag}},{display_text:w,query_text:w,trace_info:{item_id:"80b0c699d58492b56b0db7a42ba32d93",item_type:n,item_name:w,rec_info:ah}},{display_text:x,query_text:x,trace_info:{item_id:"6038ade21419c5b471473dfbe0fc02c9",item_type:n,item_name:x,rec_info:ai}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:J,data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:aj,related_name:ak}],puuid:Q,tag:a,category:"custom",uuid:al}],global:{urp_static_data:[{name:ak,value:{status_code:d,columns:[{type:f,index_name:am,key:am},{type:f,index_name:an,key:an},{type:f,index_name:ao,key:ao},{type:f,index_name:ap,key:ap},{type:f,index_name:aq,key:aq}],datas:[{send_text:v,item_type:n,rec_info:ag,display_text:v,rec_reason:a},{send_text:w,item_type:n,rec_info:ah,display_text:w,rec_reason:a},{send_text:x,item_type:n,rec_info:ai,display_text:x,rec_reason:a}],dataSize:aj,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ar,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:F,"min-height":"100%",position:as,height:F},isMaterial:c,id:ar,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:R,componentUuid:al,script:[{name:at,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:R,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:R},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:F,position:as,height:F},isMaterial:b,_id:19,id:at,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:P,voice_txt:a,tracking_info:{},uuid:Q},order:{is_auto:c,render_for:P,chart_type:"command",puuid:Q}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:I,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:G,answer_chain_name:U},is_deep_research:c,deep_thinking:c,create_time:1744630050394},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:p,docsData:[],quoteData:p},tplType:"question"},events:au,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:au,client_ip:a,question:g,user_id:y,user_name:a,trace_id:i,session_id:i,source:o,input_type:X}}],userId:y,userName:a,startTime:Y,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:p,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:p,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-sage-therapeutics-revenue-and-expenses-shift-in-q4-2024-3bc82f\u002F",config:{_app:{basePath:av,assetsPath:av,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","STR","How did Sage Therapeutics' revenue and expenses shift in Q4 2024?",1,"f26edb7d-1e7b-48f2-a0e3-0cc86171d811","intusstock","185","signal","Sage Therapeutics","llm_generated","ths_ainvest_lite_web",null,"SAGE.O",999,2001,"SAGE","Date","⚕️ What was the net income of Sage Therapeutics in Q4 2024?","📈 How does Sage Therapeutics' Q4 2024 financial performance compare to analyst expectations?","📊 How did Sage Therapeutics' operating expenses change in Q4 2024 compared to the previous quarter?","dp19317190","progress\u002Fsearching_for",1000,"searching_for","rich_text","Total Revenue","abs_国际美股领域","auto","agent","SAGE Revenue (Q4 2024), Expenses (Q4 2024)","inspect stocks","title1","code","fixed_index","Ticker","Name","Total Expenses","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Sage Therapeutics experienced a total revenue of $12.82 million during Q4 2024, reflecting a significant financial activity period for the company. However, the specific expenses for the same period are not available, which makes it challenging to provide a comprehensive analysis of the company's financial health during that time. The absence of expense data limits a detailed assessment of Sage Therapeutics' financial performance in Q4 2024.\n\n\n|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|\n|---|---|---|---|---|---|---|\n|SAGE|SAGE.O|Sage Therapeutics|2024 Q1|7902000||185|\n|SAGE|SAGE.O|Sage Therapeutics|2024 Q2|8654000||185|\n|SAGE|SAGE.O|Sage Therapeutics|2024 Q3|1.1871E7||185|\n|SAGE|SAGE.O|Sage Therapeutics|2024 Q4|1.2816E7||185|\n\n","select   stock_code,   total_revenue,   total_expenses from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'SAGE.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744630035225,"stock","Sage Therapeutics experienced a total revenue of $12.82 million during Q4 2024, reflecting a significant financial activity period for the company. However, the specific expenses for the same period are not available, which makes it challenging to provide a comprehensive analysis of the company's financial health during that time. The absence of expense data limits a detailed assessment of Sage Therapeutics' financial performance in Q4 2024[^1]",".\n\n\n``` visual\n{\"uuid\":\"dd4d236a-0998-43ce-a9aa-545db0558810\"}\n```","result_page","bar3","SAGE Total Revenue","DOUBLE","USD","market_code","2+679_496_21_554+0+0+f26edb7d-1e7b-48f2-a0e3-0cc86171d811+0e807dcf95fa27073d22f0d2f37d4189+llm_generated+aimeTagAnalysis+0+0.10985048860311508+1","2+679_496_21_554+0+0+f26edb7d-1e7b-48f2-a0e3-0cc86171d811+80b0c699d58492b56b0db7a42ba32d93+llm_generated+aimeTagAnalysis+0+0.06485211849212646+2","2+679_496_21_554+0+0+f26edb7d-1e7b-48f2-a0e3-0cc86171d811+6038ade21419c5b471473dfbe0fc02c9+llm_generated+aimeTagAnalysis+0+0.05743497610092163+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>